Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ada68032e6c5599de33d868231aaa52d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1211 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0668 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-01021 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
filingDate |
2019-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f313d438c66915fbcbae0fff82ac8c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_157c15943b553814d01daae1d07b0d09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad0158acd9437b0136d85046afc4ca22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ad843b07bc39123c251217624eeee40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0c94283a614c853e12ccacefc2061e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d1eeb337426fb1579bd282f25b7a464 |
publicationDate |
2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
TW-I723354-B |
titleOfInvention |
Engineering stem cells for cancer therapy |
abstract |
The present disclosure provides an engineered stem cell, comprising a vector comprising a polynucleotide comprising a nucleic acid sequence of suicide gene, a nucleic acid sequence of immune checkpoint gene and a natural cytotoxicity triggering receptor or a TNF-related apoptosis-inducing ligand, wherein the stem cell is a tumor-targeting cell. The present disclosure also provides a method for treating a cancer or enhancing intratumor immunity or enhancing immunity in tumor microenvironment in a subject, comprising administering an effective amount of the engineered stem cell of the present disclosure to the subject. |
priorityDate |
2018-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |